Biosynex specializes in the research, development and manufacturing of fast diagnosis tests on membrane support for health professionals (biologists, clinicians, nurses and midwives). Products are used in the tropical diseases, autoimmune diseases, emergency markers and Infectious diseases fields. The company's activity is organized around 5 areas: - manufacturing of diagnosis tests for own account; - sale of diagnosis tests supplied by other manufacturers of semi-finished products; - research and development services for third party; - sale of licenses; - sale of biological reagents.

Employees

397

Sector

Medical Equipment, Supplies & Distribution

More about the company

Quotes

Date	Price	Change	Volume
18/26/18	€0.9200	-1.71%	11,905
17/26/17	€0.9360	+0.65%	11,374
14/26/14	€0.9300	-7.00%	37,329
13/26/13	€1.000	0.00%	78,628
12/26/12	€1.000	+9.89%	96,839

Real-time Euronext Paris

More quotes

Income Statement and Estimates

More financial data

Real-time Euronext Paris 06:35:18 18/08/2026 pm IST			5-day change	1st Jan Change
0.9200 ^EUR	-1.71%		+1.10%	+54.36%

06/08	Biosynex hit by cyberattack, operational activity remains intact
11/06	Triple update for Biosynex

Market Cap	1.73Cr 2Cr 1.62Cr 1.47Cr 2.77Cr 191.07Cr 2.81Cr 19Cr 7.44Cr 96Cr 7.5Cr 7.34Cr 318.43Cr	P/E 2024	-0.43x	P/E 2025	-0.19x
Enterprise Value	7.04Cr 8.16Cr 6.61Cr 6.02Cr 11Cr 780.17Cr 11Cr 77Cr 30Cr 390.86Cr 31Cr 30Cr 1.3TCr	EV / Sales 2024	0.71x	EV / Sales 2025	0.68x
Free-Float	40.35%	Yield 2024 *	-	Yield 2025	-

06/08	Biosynex hit by cyberattack, operational activity remains intact
11/06	Triple update for Biosynex
11/06	An undisclosed buyer acquired Entire internal molecular biology business from Biosynex SA for ?4 million.	CI
25/05	Paris climbs on hopes of Middle East de-escalation
25/05	Biosynex announces the divestment of its molecular biology business
25/05	An undisclosed buyer signed a binding offer to acquire Entire internal molecular biology business from Biosynex SA for ?4 million.	CI
08/05	Biosynex SA Reports Earnings Results for the Full Year Ended December 31, 2025	CI
07/05	Biosynex SA Auditor Raises 'Going Concern' Doubt	CI
21/04	Thales, Vivendi, Mercialys, GTT... stocks to watch today in Paris
21/04	Biosynex postpones publication of annual accounts
24/03	Abivax, Ekinops, Sanofi... stocks to watch today in Paris
24/03	Observation period extended for Biosynex
06/02	A Biosynex Subsidiary to Receive $1.8 Million Grant

23/24/23	BIOSYNEX SA: CHEMBIO DIAGNOSTICS INC., A SUBSIDIARY OF BIOSYNEX, RECEIVES A GRANT FOR DEVELOPMENT OF A DPP CONGENITAL SYPHILIS ASSAY	EQ
28/23/28	Biosynex Completes Acquisition of Chembio Diagnostics, Inc.	AQ
13/23/13	Biosynex Extends Tender Offer for the shares of Chembio Diagnostics, Inc.	AQ
15/23/15	Biosynex Extends Tender Offer for the shares of Chembio Diagnostics, Inc.	AQ
01/23/01	Biosynex and Chembio Diagnostics Announce Definitive Acquisition Agreement	AQ

Biosynex Share Price

Stocks

ALBIO

FR0011005933

Medical Equipment, Supplies & Distribution

Valuation: Biosynex

Chart: Biosynex

Latest news : Biosynex

Press Releases: Biosynex

News in other languages: Biosynex

Quotes and Performance

Course Extremes

Managers and Directors: Biosynex

Latest insider transactions

Diagnostic & Testing Substances

Financials

Company Profile

Quotes

Income Statement and Estimates

07/08	Bourse : Eutelsat souffre, la tech américaine s'offre un baroud d'honneur nocturne
07/08	L'énigmatique Mister Warsh, le marché du travail et les taux
06/08	Biosynex victime d'une cyberattaque, l'activité opérationnelle préservée
06/08	BIOSYNEX SA: Cyberattaque
22/07	BIOSYNEX SA: CHIFFRE D’AFFAIRES DU 1er SEMESTRE 2026 : 44,1 M€ - PERSPECTIVES

1 day	-1.71%
1 week	+1.10%
1 month	+1.10%
3 months	-1.08%
6 months	-0.43%
Current year	+54.36%

1 week	0.91	1
1 month	0.89	1
Current year	0.56	1.57
1 year	0.46	1.57
3 years	0.46	10.92
5 years	0.46	28.78
10 years	0.46	30.38

Manager	Title	Age	Since
Larry Abensur CEO	Chief Executive Officer	71	24/06/2015
Thierry Paper CTO	Chief Tech/Sci/R&D Officer	63	01/01/2015
Oren Bitton PRN	Corporate Officer/Principal	-	-

Director	Title	Age	Since
Thierry Paper BRD	Director/Board Member	63	24/06/2015
Thomas Lamy BRD	Director/Board Member	-	24/06/2015
Larry Abensur CHM	Chairman	71	24/06/2015

Date	Insider	Type	Main position	Quantity	% Market Cap.
15/02/23	Elie Fraenckel	Buy	Director	2,500	0.0244%
15/02/23	Elie Fraenckel	Buy	Director	2,500	0.0244%
28/02/22	Larry Abensur	Buy	Chief Executive Officer	2,000	0.0180%

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
BIOSYNEX	-1.71%	+1.10%	-22.69%	-91.56%	2Cr
GUARDANT HEALTH, INC.	-1.08%	-3.31%	+174.58%	+354.77%	2.17TCr
BIOMÉRIEUX	+0.41%	-1.22%	-42.69%	-21.19%	989.74Cr
10X GENOMICS, INC.	-0.31%	-0.99%	+334.06%	+25.49%	755.56Cr
LANTHEUS HOLDINGS, INC.	-0.13%	-0.07%	+86.25%	+53.22%	658.66Cr
CARIS LIFE SCIENCES, INC.	-1.02%	-7.56%	-40.74%	-	611.25Cr
SHENZHEN NEW INDUSTRIES BIOMEDICAL ENGINEERING CO., LTD.	+0.41%	+4.96%	-12.57%	-6.88%	599.68Cr
ANDON HEALTH CO., LTD.	+3.29%	+4.62%	+87.09%	+116.06%	470.48Cr
DIASORIN S.P.A.	-0.35%	-3.03%	-12.37%	-17.31%	427.16Cr
AUTOBIO DIAGNOSTICS CO., LTD.	-2.38%	+0.06%	-21.04%	-33.49%	278.63Cr
Average	-0.39%	+0.17%	+52.99%	+42.12%	696.27Cr
Weighted average by Cap.	-0.44%	-1.04%	+92.36%	+131.72%

	2024	2025
Net sales	10Cr 12Cr 9.49Cr 8.64Cr 16Cr 1.12TCr 16Cr 111.26Cr 44Cr 561.35Cr 44Cr 43Cr 1.87TCr	9.52Cr 11Cr 8.93Cr 8.13Cr 15Cr 1.05TCr 16Cr 104.69Cr 41Cr 528.2Cr 41Cr 41Cr 1.76TCr
Net income	-4.33Cr -5.02Cr -4.07Cr -3.7Cr -6.96Cr -479.92Cr -7.06Cr -48Cr -19Cr -240.44Cr -19Cr -18Cr -799.8Cr	-5.82Cr -6.74Cr -5.46Cr -4.98Cr -9.35Cr -644.85Cr -9.48Cr -64Cr -25Cr -323.07Cr -25Cr -25Cr -1.07TCr
Net Debt	5.29Cr 6.13Cr 4.97Cr 4.52Cr 8.51Cr 586.28Cr 8.62Cr 58Cr 23Cr 293.73Cr 23Cr 23Cr 977.07Cr	5.32Cr 6.16Cr 4.99Cr 4.55Cr 8.55Cr 589.1Cr 8.66Cr 58Cr 23Cr 295.14Cr 23Cr 23Cr 981.76Cr